

10/509604#3

DT04 Rec'd PCT/PTO 27 SEP 2004

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter Haynes Hutson

Int'l Appln.
No. : PCT/GB03/01237Int'l Date
Filed : 21 March 2003 (21/03/2003)

Serial No. : (To be assigned) Case No.: T1571P

Filed : September 27, 2004

For : USE OF A BENZOFURAN DERIVATIVE FOR THE
TREATMENT OF ATTENTION DEFICIT
HYPERACTIVITY DISORDERCommissioner for Patents
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT Sept 27 2004
POSTAL MAIL NO. 22 989588077 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY For Signature
DATE Sept 27 2004

10/509604

DT04 Rec'd PCT/PTO 27 SEP 2004

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: September 27, 2004

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN RECEIVED PCT/PTO 27 SEP 2004 107509604	
				Application Number	
				Filing Date September 27, 2004	
				First Named Inventor Peter Haynes Hutson	
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	T1571P

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

September 27, 2004

Peter Haynes Hutson

T1571P

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Tarazi F. I. et al: "Dopamine D4 receptors: significance for molecular psychiatry at the millennium." MOLECULAR PSYCHIATRY. ENGLAND NOV. 1999, vol. 4, no. 6, pages 529-538

Licinio J: "The dopamine D4 receptor and attention deficit hyperactivity disorder." MOLECULAR PSYCHIATRY, ENGLAND MAY 1996, vol. 1, no. 2, May 1996, pages 83-84

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003